Timothy Cloughesy
Affiliations: | University of California, Los Angeles, Los Angeles, CA |
Google:
"Timothy Cloughesy"Mean distance: 15.14 (cluster 31) | S | N | B | C | P |
Collaborators
Sign in to add collaborator| National Brain Tumor Society | collaborator | National Brain Tumor Society |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Venneti S, Kawakibi AR, Ji S, et al. (2023) Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways. Cancer Discovery |
| Nassiri F, Patil V, Yefet LS, et al. (2023) Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial. Nature Medicine |
| Omuro A, Brandes AA, Carpentier AF, et al. (2022) Radiotherapy Combined With Nivolumab or Temozolomide for Newly Diagnosed Glioblastoma With Unmethylated MGMT Promoter: An International Randomized Phase 3 Trial. Neuro-Oncology |
| He L, Bhat K, Ioannidis A, et al. (2021) Effects of the DRD2/3 Antagonist ONC201 and Radiation in Glioblastoma. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology |
| Cloughesy TF, Petrecca K, Walbert T, et al. (2020) Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma: A Randomized Clinical Trial. Jama Oncology |
| Reardon DA, Desjardins A, Rixe O, et al. (2020) A phase 1 study of PF-06840003, an oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor in patients with recurrent malignant glioma. Investigational New Drugs |
| Peters KB, Cohen AL, Butowski NA, et al. (2020) BMX-HGG: Phase II trial of newly diagnosed high-grade glioma treated with concurrent radiation therapy, temozolomide, and BMX-001. Journal of Clinical Oncology. 38: TPS2577-TPS2577 |
| Mellinghoff IK, Van Den Bent MJ, Clarke JL, et al. (2020) INDIGO: A global, randomized, double-blind, phase III study of vorasidenib (VOR; AG-881) vs placebo in patients (pts) with residual or recurrent grade II glioma with an isocitrate dehydrogenase 1/2 (IDH1/2) mutation. Journal of Clinical Oncology. 38: TPS2574-TPS2574 |
| Arrillaga-Romany I, Kurz SC, Tarapore R, et al. (2020) Single-agent ONC201 in recurrent H3 K27M-mutant diffuse midline glioma. Journal of Clinical Oncology. 38: 3615-3615 |
| Molaie D, Lai A, Ellingson BM, et al. (2020) Phase II trial of bevacizumab and temozolomide for treatment of elderly patients with newly diagnosed glioblastoma. Journal of Clinical Oncology. 38: 2540-2540 |